Press Releases
Browse the the latest press releases from around the industry. Want to filter press releases by date, keyword, and more? Search here.
THE LATEST
Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected “VIVI Cap Smart” device
Celebrating A Year of Extraordinary Achievement
Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist
Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with medication management for individuals using life-saving medication
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients - - Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-BCMA exposed patients -